BridgeBio Oncology Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Plans
During the three months ended September 30, 2026, the following directors and executive officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated the contracts, instructions or written plans for the purchase or sale of our securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K), as set forth in the table below.
| Name | Position | Action | Date of Action | Duration of Trading Arrangement | Aggregate Number of Securities(1) | Description of Trading Arrangement |
|---|---|---|---|---|---|---|
| Pedro J. Beltran, Ph.D. | Chief Executive Officer | Adoption | 8/19/2026 | Until 10/31/2027, or such earlier date upon which all transactions are completed or expire without execution. | Up to 203,904 shares | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to terms of the trading plan |
| Marc Cobo | Principal Accounting Officer | Adoption | 7/24/2026 | Until 10/20/2027, or such earlier date upon which all transactions are completed or expire without execution. | Up to 610 shares | Sales of shares of the Company’s common stock pursuant to terms of the trading plan |
(1) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan and will be net of shares withheld to satisfy tax withholding obligations which is not yet determinable.
Immaterial Correction of Prior Period Financial Statements
Subsequent to the issuance of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company identified errors related to net loss per share and weighted average shares outstanding previously disclosed in each of the Quarterly Reports on Form 10-Q for the periods ended March 31, 2026 and June 30, 2026. The errors relate to the net loss per share amounts for the quarters ended March 31, 2026 (unaudited) and June 30, 2026 (unaudited), and the six months ended June 30, 2026 (unaudited), due to incorrect inputs, including inappropriate use of shares in thousands as compared to actual shares, for the calculation of net loss per share.
The errors have no impact on the consolidated balance sheet, consolidated statements of operations (excluding the weighted average shares outstanding and net loss per share presentation), comprehensive loss, stockholders' equity, and cash flows. The Company has evaluated the quantitative and qualitative factors for these misstatements and has concluded it was not material, individually or in the aggregate, to the financial statements of prior periods.
The Company will prospectively correct the 2026 errors in the Condensed Consolidated Financial Statements that will be presented in its Quarterly Reports on Form 10-Q for the periods ending March 31, 2027 and June 30, 2027. The following tables reflect the correction on the affected line items in the Company’s previously reported Condensed Consolidated Financial Statements for the periods ended March 31, 2026 and June 30, 2026:
| Previously Reported | Three Months Ended March 31, 2026 | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|---|
| Net loss per share attributable to common stockholders, basic and diluted | $(526.11) | $(705.20) | $(1,230.89) |
| Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted | 80,032 | 80,054 | 80,072 |
| As corrected | Three Months Ended March 31, 2026 | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.53) | $(0.70) | $(1.23) |
| Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted | 80,031,630 | 80,111,225 | 80,072,183 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.